Special Issue "New Approaches to the Atrial Fibrillation Management"
Deadline for manuscript submissions: closed (31 January 2020).
Interests: mapping of atrial fibrillation in order to identify novel targets for therapy; arrhythmias in patients with congenital heart disease
Interests: role of protein homeostasis and the protein quality control system underlying atrial fibrillation; novel druggable targets for the therapy of atrial fibrillation
Special Issues and Collections in MDPI journals
Age-related, progressive arrhythmia atrial fibrillation (AF) is the cardiovascular epidemic of the 21th century. The increase in the number of patients with AF is associated with the ageing of populations suffering from a variety of cardiovascular diseases because of the improved clinical care. The development of AF depends on the presence of triggers, initiators, and substrates, and is treated with drugs, implantable devices (electrical stimulation/defibrillation therapy), and catheter-based ablative therapy. Unfortunately, the currently available therapies are moderately effective and can have serious side-effects. There are several explanations for therapy failure. In case of trigger-driven AF, recurrences after ablative therapy are the result of a reconduction across the ablation lesions. In substrate-mediated patients, AF is caused by “electropathology”, which is defined as abnormalities in electrical impulse formation or conduction as a result of the structural damage of cardiac tissue. The exact electrical and molecular mechanisms underlying AF are at present only partly known. The severity of electropathology determines which treatment modality is the most effective, and is therefore indispensable in guiding therapy. However, there are insufficient (pharmaco) therapeutic tools to target the underlying electropathological substrate. Hence, the development of patient-tailored diagnostic tools and innovative therapies is of paramount importance in order to improve arrhythmia-free survival. In the past decades, many novel therapies for patients with AF have been developed with a variety of targets, ranging from the prevention of thrombo-embolic complications, to complex ablation strategies. The aim of this Special Issue is to discuss the contribution of novel approaches to advances in the management of patients with AF.
Prof. Dr. Natasja M.S. de Groot
Prof. Dr. Bianca Brundel
Manuscript Submission Information
Manuscripts should be submitted online at www.mdpi.com by registering and logging in to this website. Once you are registered, click here to go to the submission form. Manuscripts can be submitted until the deadline. All papers will be peer-reviewed. Accepted papers will be published continuously in the journal (as soon as accepted) and will be listed together on the special issue website. Research articles, review articles as well as short communications are invited. For planned papers, a title and short abstract (about 100 words) can be sent to the Editorial Office for announcement on this website.
Submitted manuscripts should not have been published previously, nor be under consideration for publication elsewhere (except conference proceedings papers). All manuscripts are thoroughly refereed through a single-blind peer-review process. A guide for authors and other relevant information for submission of manuscripts is available on the Instructions for Authors page. Journal of Clinical Medicine is an international peer-reviewed open access semimonthly journal published by MDPI.
Please visit the Instructions for Authors page before submitting a manuscript. The Article Processing Charge (APC) for publication in this open access journal is 2200 CHF (Swiss Francs). Submitted papers should be well formatted and use good English. Authors may use MDPI's English editing service prior to publication or during author revisions.
- mapping-guided therapy
- novel pharmacological therapies
- preventive pacing
- ablation therapy
- left atrial appendage occluding devices
- surgical AF therapy
- novel anti-coagulation therapies